Brimarafenib not checked

MapKure, LLC · BGB-3245

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-rafenib: Raf kinase inhibitors WHO name stem
How it’s given
“administered orally (PO) once daily at doses specified in the description of each arm”In the company’s words, NCT04249843 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor, Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers, Solid Tumor, B-Raf Mutation-Related Tumors
Main trialPhase 1/2
“A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.”In the company’s words, NCT05580770 on ClinicalTrials.gov
Other names
BGB-3245

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 15 Jan 2025 Mirdametinib + BGB-3245 in Advanced Solid Tumors
Phase 1Terminated 10 Mar 2025 A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Phase 1Terminated 8 Aug 2025 Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Brimarafenib

Following is part of Solo: you see every change to Brimarafenib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in